VINC 0.37 Vincerx Pharma, Inc.
| Range: | 0.362-9.372 | Vol Avg: | 457589 | Last Div: | 0 | Changes: | 0 |
| Beta: | 1.17 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed May 27 2020 | Empoloyees: | 42 | ||
| CUSIP: | 92731L106 | CIK: | 0001796129 | ISIN: | US92731L1061 | Country: | US |
| CEO: | Dr. Ahmed M. Hamdy M.D. | Website: | https://vincerx.com | ||||
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Stock Details
Positive 0.39
What Makes Vincerx Pharma (VINC) a New Buy Stock
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, ...
zacks.com·Thu Oct 10 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow